Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Therapeutic Advances in Medical Oncology|June 18, 2020
Tivozanib in renal cell carcinoma: a new approach to previously treated diseaseNicholas J Salgia, Zeynep B Zengin, Sumanta K Pal
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2025
Microbiome Modulation for the Treatment of Solid NeoplasmsRegina Barragan-Carrillo, Zeynep B Zengin, Sumanta K Pal
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 22, 2024
Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic AdvancesNicholas J Salgia, Zeynep B Zengin, Sumanta K Pal, et al.
Cancer Journal (Sudbury, Mass.)|September 18, 2020
Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney CancerZeynep B Zengin, Nicholas J Salgia, Alexander Chehrazi-Raffle, et al.
Cancers|May 14, 2022
Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future DirectionsAmeish Govindarajan, Daniela V Castro, Zeynep B Zengin, et al.
Urologic Oncology|November 29, 2021
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinomaZeynep B Zengin, Alex Chehrazi-Raffle, Nicholas J Salgia, et al.
Clinical Genitourinary Cancer|September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney CancerZeynep B Zengin, Sumanta K Pal, David F McDermott, et al.
Clinical Genitourinary Cancer|December 12, 2022
Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint InhibitorsNeal S Chawla, Nicolas Sayegh, Nishita Tripathi, et al.
Clinical Genitourinary Cancer|June 30, 2023
Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal StudyCristiane Decat Bergerot, Errol J Philip, Ameish Govindarajan, et al.
JCO Precision Oncology|April 7, 2023
Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell CarcinomaAlexander Chehrazi-Raffle, Ramya Muddasani, Nazli Dizman, et al.
Pageof 3